



Genenta presents preliminary pre-clinical and clinical data from a Phase 1/2 study in patients with glioblastoma multiforme at American Society of Gene & Cell Therapy

May 4, 2020

MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they will present preliminary pre-clinical and clinical data from the TEM-GBM_001 clinical trial at the international scientific meeting: American Society of Gene & Cell Therapy (ASGCT), May 12-15, 2020.

Dr Bernhard Gentner, Co-Founder of Genenta, will present relevant data for the TEM-GBM_001 clinical trial on 15th of May.